MedTrace Logo

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

NCT00819221 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-08-30

No results posted yet for this study

Summary

The study will be an open label, multicenter, dose finding study. Depending on the tolerated dose up to 7 dose levels will be explored in this study, approximately 33 patients (21-54 depending on number of cohorts) may be enrolled into this study. Three patients will be initially dosed in each cohort. The primary objective of this study is to determine the recommended dose (RD) of twice daily oral doses of AZD2281 either as intermittent therapy for 7 days out of a 28-day schedule or given continuously, administered in combination with liposomal doxorubicin to patients with advanced solid tumors.

Conditions

Interventions

DRUG

AZD2281

capsules, oral, bd, 2 months

DRUG

liposomal doxorubicin

once every 4 weeks at 40mg/m2

Sponsors & Collaborators

Principal Investigators

  • Jane Robertson, BSc, MBCHB, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-05
Primary Completion
2011-11-30
Completion
2021-12-22

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00819221 on ClinicalTrials.gov